Real-time enrollment status for this prostatic neoplasms, castration-resistant clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 4:04 PM UTC
| NCT Number | NCT07225946 |
| Recruiting Status | Recruiting |
| Condition | Prostatic Neoplasms, Castration-Resistant |
| Phase | PHASE3 |
| Target Enrollment | 800 participants |
| Active Locations | 59 sites in the US |
| Sponsor | Janssen Research & Development, LLC |
| Last Updated on CT.gov | September 25, 2026 (2 weeks ago) |
As of October 12, 2026: Clinical trial NCT07225946 is currently recruiting participants. This phase3 study for prostatic neoplasms, castration-resistant is actively seeking new participants at 59 locations across the United States. The study is sponsored by Janssen Research & Development, LLC. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07225946 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 59 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07225946 was last updated 2 weeks ago (September 25, 2026). HelloStudys verifies this status automatically.